Guardant Health Earnings Call Highlights Growth And Burn

Guardant Health ((GH)) has held its Q4 earnings call. Read on for the main highlights of the call.

Guardant Health’s latest earnings call struck an optimistic tone around growth and execution, underscored by rapid revenue expansion, rising test volumes, and improving margins across its oncology and screening businesses. Management emphasized a clearer path toward profitability, but acknowledged that heavy Shield screening investments, reimbursement uncertainty, and regulatory timing keep the near-term financial picture complex for investors.

Strong Top-Line Growth

Guardant reported Q4 2025 revenue of $281.3 million, a 39% jump year over year, with full-year revenue reaching $982.0 million, up 33%. Management guided 2026 revenue to a range of $1.25 billion to $1.28 billion, implying another 27% to 30% growth and signaling confidence that demand across its oncology and screening franchises will remain robust.

Oncology Growth and Volume Expansion

The core oncology business remained the engine of the company, with Q4 oncology revenue of $189.9 million, up 30% year over year, on roughly 79,000 tests, a 38% volume increase. For 2025 as a whole, oncology revenue hit $683.6 million on about 276,000 tests, representing 26% and 34% growth respectively, and management expects volumes to keep expanding at roughly 30% in 2026.

Shield Screening Traction

Guardant’s Shield blood-based colorectal cancer screening test showed accelerating traction, generating $35.1 million in Q4 on about 38,000 tests versus 24,000 in Q3, and $79.7 million for 2025 on around 87,000 tests. The company highlighted a 93% adherence rate across the first 100,000 Shield orders and secured ADLT reimbursement at $1,495 through late 2027, strengthening the economics of the screening franchise.

Margin Improvement and Cost Reductions

Profitability metrics moved in the right direction, with non‑GAAP gross margin improving to 66% in Q4 and for the full year, up from 63% and 62% respectively in the prior period. Cost of goods fell sharply in key products, as Reveal’s cost per test dropped from over $1,000 in Q3 2024 to under $500, while Shield’s non‑GAAP gross margin climbed to 52% with cost per test exiting 2025 around $450.

Biopharma & Data Momentum and CDx Approvals

Biopharma and data revenue provided a steady secondary growth pillar, rising 18% in 2025 to $210.1 million, with Q4 revenue of $54.0 million up 9%. The company now counts 25 companion diagnostic approvals, including five new approvals in the last six months and its first FDA nod for Guardant360 in colorectal cancer, which could deepen pharma partnerships and test demand over time.

Improving Profitability Trends

Adjusted EBITDA loss narrowed to $64.9 million in Q4 from $78.4 million a year earlier and to $220.9 million for 2025 versus $257.5 million in 2024, showing improving operating leverage despite ongoing investment. Free cash flow burn improved by $42 million to $233 million for the year, suggesting that scale and cost efficiencies are beginning to offset the weight of growth spending.

Strong Cash Position and Strategic Investments

Guardant ended 2025 with roughly $1.3 billion in cash, bolstered by financing activity and the MetaSight acquisition, which management believes gives the company ample runway to execute its growth plan. The MetaSight deal, with $59 million upfront and up to $90 million in contingent payments, is aimed at accelerating R&D and expanding a multi‑disease testing pipeline, reinforcing the long‑term innovation story.

Clear 2026 Growth Drivers and Visibility

Management outlined specific 2026 drivers, including oncology revenue growth of 25% to 27% on about 30% volume growth and screening revenue of $162 million to $174 million from 210,000 to 225,000 Shield tests. Non‑GAAP gross margin is expected at 64% to 65%, with free cash flow burn reduced to $185 million to $195 million and the core business, excluding Shield screening, projected to be free cash flow positive.

Continued Operating Losses and Cash Burn

Despite progress, the company remains in the red, with adjusted EBITDA negative $64.9 million in Q4 and $220.9 million for 2025 and total free cash flow burn at $233 million. Management noted that screening alone accounted for roughly $220 million of 2025 cash burn and is expected to drive a similar level of burn in 2026, keeping company-wide breakeven out of reach in the near term.

High Operating Expenses

Non‑GAAP operating expenses reached $260.0 million in Q4, up 21% year over year, and $903.7 million for the full year, a 19% increase that landed modestly above prior guidance. The overshoot was tied to higher bonus accruals and reinvestment to expand screening commercialization, with 2026 OPEX projected to climb further to $1.03 billion to $1.05 billion, or 14% to 16% growth.

Shield Investment Weighting and Near-Term Profit Drag

Management stressed that Shield requires heavy upfront commercial spending across sales expansion, EMR integrations, and direct-to-consumer pilots, which will keep screening deeply cash‑flow negative in 2026 with an expected $220 million burn. As a result, Guardant now targets company‑wide free cash flow breakeven only by the end of 2027, even as the underlying oncology business turns positive earlier.

ASP and Mix Pressure for Shield

While Shield’s average selling price exited Q4 around $850, management warned that the blended ASP will likely fall in 2026 as test mix shifts toward under‑65 commercial patients. This tilt toward commercially insured volumes could pressure near-term per-test revenue relative to Q4 exit levels, even as total Shield volumes and absolute screening revenue continue to climb.

Dependence on U.S. Market and Execution Risks

The outlook remains heavily U.S.-centric, with international revenue expected to be a minor contributor in 2026 and leaving growth more exposed to domestic policy and competitive shifts. Management also highlighted several potential upside levers, such as new approvals, co-promotion benefits, and guideline changes, but noted these are not included in the base case and represent execution and regulatory risk if they fail to materialize.

Competitive and Evidence-Generation Uncertainty in MCED

In multi-cancer early detection, Guardant acknowledged an uncertain competitive landscape following recent peer trial setbacks, which have muddied investor expectations for the field. The company is leaning on large-scale real-world data collection and patient opt-ins to support future regulatory pathways, but timelines, required evidence thresholds, and ultimate outcomes remain unclear.

Reimbursement and Regulatory Timing Uncertainties

Management flagged several reimbursement and regulatory items as important but not guaranteed catalysts, including potential changes to Guardant360 pricing and expanded decisions for Reveal monitoring. None of these factors are fully embedded in the 2026 guide, creating both upside optionality and a degree of risk around the pace at which the company can improve margins and accelerate cash generation.

Forward-Looking Guidance and Outlook

Guardant’s 2026 guidance calls for $1.25 billion to $1.28 billion in revenue, 64% to 65% non‑GAAP gross margin, and non‑GAAP operating expenses of $1.03 billion to $1.05 billion, with free cash flow burn narrowing to $185 million to $195 million. Management expects the core oncology and biopharma businesses to be modestly free cash flow positive at the midpoint, while sustained, deliberate Shield investment remains the main drag on near-term profitability and cash.

Guardant’s earnings call painted the picture of a fast-growing diagnostics company trading near-term profitability for a bigger long-term screening opportunity, backed by a solid cash cushion and visible oncology growth. For investors, the story hinges on whether Shield can scale into its heavy investment, and whether regulatory and reimbursement milestones arrive on time to turn today’s burn into tomorrow’s leverage.